Neuropeutics Inc: A partnership to advance treatment for MND/ALS
We are collaborating with Neuropeutics Inc to develop a small molecule therapy targeting TDP-43 pathology in motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS).
Overview
TDP-43 protein aggregation is a key driver of neurodegeneration in MND/ALS. By combining expertise and resources with Neuropeutics Inc, we are accelerating the development of JRMS-22, a promising, novel small molecule therapy for MND designed to prevent and reverse TDP-43 protein aggregation. By combining expertise and resources, this collaboration seeks to bring hope to patients worldwide.
About the collaboration
Through this partnership we are advancing ‘JRMS-22’ towards clinical development. Originally identified and validated by Drs. Marc Shenouda and Janice Robertson at the University of Toronto and later developed at Neuropeutics Inc, this small molecule has shown potential in cellular and animal models to counteract TDP-43 protein mislocalization and toxicity.
We are contributing our scientific expertise and proprietary assays, while Neuropeutics Inc is leveraging its deep knowledge of neurodegenerative disease mechanisms. Together, we aim to develop a lead candidate that could change the treatment landscape for MND/ALS and related neurodegenerative disorders.
There is an urgent need for new, effective treatments for MND/ALS, and this partnership represents a crucial step toward developing therapies not only for ALS but also for related conditions. By combining our scientific expertise and resources, we hope to find a solution that will transform the lives of the hundreds of thousands affected by this devastating disease.”
Paul Wright, Head of Motor Neuron Disease, LifeArc
About MND/ALS
MND/ALS is a progressive, fatal neurodegenerative disease that affects more than 300,000 people worldwide. It leads to the gradual loss of motor neurons in the brain and spinal cord, causing severe physical disability, loss of independence, and ultimately, paralysis. The typical prognosis after diagnosis is 2–5 years, and there are currently no cures.
Beyond the devastating personal impact, MND/ALS imposes a significant financial burden on patients, families, and healthcare systems due to the high costs of treatment, assistive devices, and caregiving. There is an urgent need for effective therapies to halt the progression of the disease or even reverse it.
Impact of this partnership
This partnership represents a critical step forward in addressing the unmet medical need for MND/ALS. If successful, the development of ‘JRMS-22’ could transform treatment and offer hope of a better life to patients and families affected by MND/ALS worldwide.
Contact us
In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. If you would like your data to be removed, please email info@lifearc.org.
Please see our Privacy Policy in relation to the personal data you submit to us through this page.
